Innovative and positioned across the entire value chain, the drug, in vitro diagnostics and medical device industries are a strategic sector with a considerable economic weight in France. With a growing competitive intensity and a complexification of health product needs, they now need to rethink their positioning and their modes of operation.
The integration of industry of the future technologies / industry 4.0 (particularly the cloud, cybersecurity, big data, artificial intelligence, robotics, digitalsimulation, connected devices (IoT) and augmented reality) within the value chain, proves to be one of the main levers of action to answer these issues. But their adoption on a large scale remains limited and uneven depending on the activity, two essential conditions for success.
In this context, the General Directorate of Enterprises (DGE), the G5 Santé (top 8 french health industry players), the Alliance for Life Sciences and Health (Aviesan) and the French Federation of Health Industries (FEFIS), commissioned OpusLine to conduct a study on the issues for the sector of health industry.
After making a state of play of the French health industry, the study details, for each component of the value chain, the existing and potential uses of industry 4.0 technologies. It then identifies the conditions and factors to accelerate the adoption of these solutions, and then makes recommendations aimed at facilitating the creation of a collective, secure and coordinated chain of health data, to enable all stakeholders to take action, embrace digital solutions and foster the emergence of a more integrated health system.